Szentiamide (1) a new cyclic hexadepsipeptide was isolated from the culture broth of the entomopathogenic bacterium Xenorhabdus szentirmaii DSM 16338 T . The structure was elucidated by analysis of one-and two-dimensional NMR spectra and high resolution mass spectrometry. The amino acids were determined to be D-leucine, L-threonine, D-phenylalanine, D-valine, L-tyrosine and L-tryptophane after hydrolysis and derivatization with D-FDVA [N  -(2,4-dinitro-5-fluorophenyl)-D-valinamide].
Xenorhabdus szentirmaii DSM 16338 T was described by Lengyel et al. (2005) [1a] together with three other species of the genus Xenorhabdus. The genus belongs to the family Enterobacteriaceae and is closely related to the genus Photorhabdus. Species of both genera, Xenorhabdus and Photorhabdus, live in association with entomopathogenic nematodes. X. szentirmaii DSM 16338 T was isolated from the nematode Steinernema rarum. The nematodes and the bacteria form a symbiotic relationship which enables them to effectively kill insects. [1a] . Despite the close association with the nematodes, Photorhabdus and Xenorhabdus species are very well able to live without their hosts [1b] . Thus, they can easily be grown in complex media under laboratory conditions, where they also produce a number of secondary metabolites. Therefore, apart from the described high molecular weight toxin complexes which very likely play the major role in killing the insects [1c,1d] [2a] , which was known as one of the main metabolites of this bacterium, we detected a couple of so far unidentified peptides and the new depsipeptide szentiamide (1). The molecular formula C 45 H 55 N 7 O 9 was deduced from the value obtained by a high resolution mass measurement (HRESIMS) and was in good agreement with the NMR data. The molecular formula implied 22 degrees of unsaturation, which was consistent for seven carbonyl groups, one mono-substituted aromatic ring (belonging to phenylalanine), one di-substituted aromatic ring (tyrosine), an indole substructure (tryptophane) and one double bond equivalent necessary for the cyclization of the molecule. The structure was shown to consist of six amino acids and accordingly the 13 C NMR spectrum included six signals of quaternary carbons with shifts corresponding to ester/ amide carbons ( C 170.0 to  C 175.1 ppm). One further carbon signal, C-45, was shifted nearly as far downfield to  C 164.0 and showed an HSQC correlation to a proton signal appearing at 8.27 ppm, thus giving evidence of an correlations to the leucine carbonyl group C-39 ( C 173.5) could be observed. The same carbon showed long range coupling to NH-36 ( H 8.29) which coupled with the threonine -proton H-36 and thus connected the leucine to the cyclic part of the molecule. The proton of the methine-group of threonine, CH-37 ( H 5.53,  C 71.6), was shifted relatively far downfield, which proved it to be linked to the next amino acid by an ester bond. As H-37 did not only show an HMBC correlation to its neighbouring methyl group CH 3 -38 ( H 1.19,  C 16.6), but also to C-1 ( C 171.1) of the tryptophane moiety, the ester bond had to exist between the tryptophane and the threonine moiety. Within the threonine substructure, H 3 -38 coupled to C-37 as well as to C-36 ( C 56.1) and the amide carbon C-35 ( C 170.0). NH-27 ( H 7.74) was proven to be the link to the phenylalanine part of the structure by its HMBC coupling to C-35 on the one hand, and its COSY correlation to the phenylalanine -proton H-27 ( H 4.75) on the other hand. The aromatic methine groups CH-30 ( H 7.28,  C 129.9) to CH-34 ( H 7.28,  C 129.9) of the phenylalanine moiety formed a coherent spin system with long range couplings to the methylene carbon C-28 ( C 37.2). The corresponding protons H 2 -28 ( H 3.21) did not only show HMBC correlations to the aromatic protons, but also to C-27 ( C 58.7) and the carbonyl carbon C-26 ( C 174.2). The following amino acid was valine which could unequivocally be proven by the correlations of NH-22 ( H 7.60) to C-26 ( C 174.2) as well as to H-22 ( H 4.04). The two valine methyl groups CH 3 -24 ( H 0.59,  C 19.3) and CH 3 -25 ( H 0.76,  C 18.9) coupled with the methine group CH-23 ( H 1.73,  C 31.4) which showed an HMBC correlation to the carbonyl C-21 ( C 175.1). The next amino acid had to be tyrosine as evidenced by the correlations of the according NH-group, 13-NH ( H 7.98). Predominant in the tyrosine part of the molecule were two doublets accounting for two protons each, CH-16/20 ( H 7.00,  C 130.6) and CH-17/19 ( H 6.70,  C 116.0), which proved the presence of a para-substituted aromatic ring. Final confirmation of the tyrosine part was obtained by the observed couplings within this partial structure. The HMBC correlation from the methine group CH-13 ( H 4.48,  C 57.1) to the quaternary carbon C-12 ( C 170.9) made this the carbonyl carbon belonging to tyrosine. In accordance with the other amino acid linkages the Cyclodepsipeptide from Xenorhabdus szentirmaii Natural Product Communications Vol. 6 (9) 2011 1249 termination of the sequence with tryptophane was deduced from the couplings of NH-2 ( H 7.09) to the carbonyl C-12 and the methine CH-2 ( H 4.65,  C 54.2). The signals of the indole partial structure included the spin system from CH-6 ( H 7.39,  C 112.2) through to CH-9 ( H 7.60,  C 119.1) and one aromatic singlet CH-11 ( H 7.20,  C 124.6). HMBC correlations from the methylene group CH 2 -3 to carbons of the indole ring, C-4, C-10 and C-11, as well as to C-1 completed the tryptophane substructure. The connection of C-1 to the threonine substructure was already delineated above. Thus, the cyclic nature of the depsipeptide could be proven and the planar structure of szentiamide definitely established. The absolute configuration of 1 was determined by derivatizing the amino acids with D-FDVA [N  -(2,4-dinitro-5fluorophenyl)-D-valinamide] and comparison with standards after HPLC-UV/MS analysis. Thus, the amino acids were determined to be D-leucine, L-threonine, D-phenylalanine, D-valine, L-tyrosine and L-tryptophane.
Similar as shown for the xenofuranones [2a] , also isolated from Xenorhabdus szentirmaii DSM16338 T , szentiamide did not show any activity in a number of bioassays (see experimental section). The production of antimicrobial agents very often can be satisfactorily explained by activity against competitors present in the environment [2b] . Xenorhabdus species certainly benefit from the synthesis of compounds which are for example toxic for the infected insects or which are able to serve as mediators of their complex life cycle. Without a doubt, there are a number of possible biological functions of szentiamide which would be of advantage for the producer and could be considered for further research.
Among secondary metabolites reported from Xenorhabdus species, compounds with an indole substructure, such as nematophin [1f] or 3-(2'-Acetoxy-3'-oxo-4'methylpentyl)-indole [2c], form a large group. Recent publications [3a] described lysine rich peptides similar to the xenobovides [3b] in which branched-chain amino acids are predominant. 1 is a depsipeptide largely composed of aromatic and branched chain amino acids and thus fits very well into the spectrum of compounds already known from Xenorhabdus. The abundance of peptides in extracts from Photorhabdus and Xenorhabdus cultures is in good accordance with the occurrence of a large number of nrps (non ribosomal peptide synthetase) gene clusters in their genomes [4] . Contrary to the known Xenorhabdus metabolites, szentiamide is functionalized with an N-formyl group which is known from other microbial secondary metabolites [5] . The most prominent example are very likely the gramicidins whose biosyntheses include the N-formylation of an N-terminal valine or isoleucine residue. As a consequence the presence of a formylation domain in the corresponding non ribosomal peptide synthetase has been postulated and confirmed [5] . The N-formylation of the starter amino acid is a rare event in non ribosomal peptide synthesis, which makes szentiamide a biosynthetically interesting compound.
Experimental
General: Optical rotation, Perkin Elmer model 241 polarimeter; UV NanoVue (GE Healthcare) spectrometer; NMR, Bruker DRX500 spectrometer; High-resolution MS, MicrOTOF-II, Bruker Daltonics) with positive electrospray ionization. Analytical reversed phase HPLC-UV/MS experiments were performed using a C 18 column (Phenomenex Onyx Monolithic C18, 100 × 3.00 mm) applying an H 2 O (A)/MeCN (B) gradient with 0.1% HCOOH added to both solvents (gradient: 0 min 5% B, 4 min 60% B, 6 min 100% B; flow 2 mL/min) on a VWR Hitachi Elite LaChrom system coupled to an ESI-ion trap detector (Esquire 4000, Bruker Daltonics). Preparative HPLC was carried out using either a LaPrep HPLC system with a P110 pump, a P311 UV-detector, a Labocol vario-200 fraction collector, a Smartline 3900 autosampler and a Phenomenex Gemini-NX 10 m C18 110 A AX, 100 x 50 mm column or a Merck Hitachi system consisting of an L-7150 pump, an L-2200 autosampler, an L-2450 diode array detector and a Phenomenex Gemini C18 110A AXIA, 100 x 21.20 mm column.
Organism and Cultivation:
Xenorhabdus szentirmaii DSM 16338 T was purchased from the DSMZ (German Collection of Microorganisms and Cell Cultures). Agar plates with TSB30 medium (30 g Tryptic Soy Broth and 15 g Agar per L demineralised water) were inoculated with cryoconserved cultures of strain DSM 16338 T and incubated for 7 days at 28 °C. These cultures were used to inoculate 10 x 1 L (in 2L-Erlenmeyer flasks) of liquid TSB30 medium. These cultures were shaken at 120 rpm and 28 °C and harvested after 8 days.
Isolation of szentiamide:
The culture broth (10 L) was homogenised with an Ultra Turrax T25 basic (IKA-Werke GmbH and Co., Staufen, Germany) at 16,000 rpm for 30 s and extracted with 20 L EtOAc by partitioning. The resulting organic extract was dried, dissolved in MeOH and subjected to preparative HPLC with a gradient of MeCN and H 2 O supplemented with 0.1% formic acid. The gradient started with 10% MeCN, which was increased to 60% after 17 min and 100% after 22 min. A crude fraction (30.3 mg) containing 1 eluted at 9.1 min. Further purification was carried out with a gradient beginning 40% ACN which was held for seven minutes and then increased to 80% until minute 14 yielded 9.7 mg 1 (yield 0.0001% ) with a retention time of 5.7 min.
Preparation and analysis of D-and L-FDVA derivatives:
Compound 1 (3 mg) was hydrolyzed by heating in HCl (6 M; 1 mL) for 20 h at 110°C. The hydrolysate was dried under a flow of nitrogen and dissolved in 250 L H 2 O. A 1% (w/v) solution (100 L) of D-FDVA in acetone was added to an aliquot (50 L) of the acid hydrolysate solution (or to 50 L of a 50 mM solution of the respective amino acid). After addition of a NaHCO 3 solution (1 M; 40 L) and DMSO (70 L) the mixture was incubated at 60°C for 2 hours. The reaction was stopped by adding 30 L HCl (2 M). The samples were diluted 100-fold with
